Literature DB >> 1352961

Ankylosing spondylitis and HLA-B27: restriction fragment length polymorphism and sequencing of an HLA-B27 allele from a patient with ankylosing spondylitis.

C M Higgins1, T Lund, M E Shipley, A Ebringer, M Sadowska-Wroblewska, R K Craig.   

Abstract

Two groups of patients with ankylosing spondylitis (AS) from England and Poland were examined for restriction fragment length polymorphisms (RFLPs) associated with the disease. No preferential association was found between the 9.2 kb PvuII fragment in HLA-B27 positive patients with AS compared with HLA-B27 healthy subjects as had been previously reported. In the English group, however, a 14 kb PvuII fragment was more common in HLA-B27 positive subjects with AS than in normal controls. Also 4.6 and 3.7 kb PvuII fragments were more prevalent in subjects without AS than in the group with AS, but these results were confined to the English group. Furthermore, the sequence of an HLA-B*2705 gene isolated from a patient with AS was examined, and no significant differences were found compared with the sequence isolated from a healthy subject. There do not seem to be significant genetic differences in the coding or in the regulatory region in HLA-B27 alleles, in subjects with or without AS.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1352961      PMCID: PMC1004768          DOI: 10.1136/ard.51.7.855

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  25 in total

1.  Characterization of the class I HLA 9.2-kb PVU II restriction fragment length polymorphism. Linkage to HLA-A and lack of disease association.

Authors:  J M Ahearn; J J Calomiris; F M Wigley; D A Jabs; W B Bias; M C Hochberg
Journal:  Arthritis Rheum       Date:  1989-07

2.  Association between ankylosing spondylitis and a 9.2 kb Pvu II class I HLA DNA restriction fragment: a reassessment.

Authors:  J P Durand; J D Taurog
Journal:  J Rheumatol       Date:  1988-07       Impact factor: 4.666

3.  Structural analysis of an HLA-B27 population variant, B27f. Multiple patterns of amino acid changes within a single polypeptide segment generate polymorphism in HLA-B27.

Authors:  S Rojo; P Aparicio; S Y Choo; J A Hansen; J A López de Castro
Journal:  J Immunol       Date:  1987-08-01       Impact factor: 5.422

Review 4.  The relationship between Klebsiella infection and ankylosing spondylitis.

Authors:  A Ebringer
Journal:  Baillieres Clin Rheumatol       Date:  1989-08

5.  Ankylosing spondylitis: klebsiella and HL-A B27.

Authors:  R Ebringer; D Cooke; D R Cawdell; P Cowling; A Ebringer
Journal:  Rheumatol Rehabil       Date:  1977-08

Review 6.  The cross-tolerance hypothesis, HLA-B27 and ankylosing spondylitis.

Authors:  A Ebringer
Journal:  Br J Rheumatol       Date:  1983-11

7.  Molecular analysis of the variant alloantigen HLA-B27d (HLA-B*2703) identifies a unique single amino acid substitution.

Authors:  S Y Choo; T St John; H T Orr; J A Hansen
Journal:  Hum Immunol       Date:  1988-03       Impact factor: 2.850

8.  Absence of polymorphism between HLA-B27 genomic exon sequences isolated from normal donors and ankylosing spondylitis patients.

Authors:  H L Coppin; H O McDevitt
Journal:  J Immunol       Date:  1986-10-01       Impact factor: 5.422

9.  Gene conversion-like mechanisms may generate polymorphism in human class I genes.

Authors:  G H Seemann; R S Rein; C S Brown; H L Ploegh
Journal:  EMBO J       Date:  1986-03       Impact factor: 11.598

10.  Antibody activity in ankylosing spondylitis sera to two sites on HLA B27.1 at the MHC groove region (within sequence 65-85), and to a Klebsiella pneumoniae nitrogenase reductase peptide (within sequence 181-199).

Authors:  C Ewing; R Ebringer; G Tribbick; H M Geysen
Journal:  J Exp Med       Date:  1990-05-01       Impact factor: 14.307

View more
  1 in total

1.  Two color analysis of HLA-B27 antigen by flow cytometer--a comparative study by conventional microlymphocytotoxicity, DNA genotyping polymerase chain reaction and flow cytometric measurement.

Authors:  S J Chou; N S Lai; J P Su; J L Wu; J L Lan
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.